Clinical trial
An Open-label, Multi-center, Phase II Umbrella Study to Assess Efficacy of Targeted Therapy or Immunotherapy Directed by Next Generation Sequencing (NGS) in Chinese Patients With Advanced NSCLC (TRUMP)
NCT03574402 is registered in ClinicalTrials.gov with Guangdong Association of Clinical Trials as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Multi-center, Phase II Umbrella Study to Assess Efficacy of Targeted Therapy or Immunotherapy Directed by Next Generation Sequencing (NGS) in Chinese Patients With Advanced NSCLC (TRUMP)
- Lead sponsor
- Guangdong Association of Clinical Trials
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- July 9, 2018
- Completion date
- December 30, 2024
- Enrollment
- 400 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.